Anavex Life Sciences (AVXL) 7.49 $AVXL
Covered Call Alerts For Anavex Life Sciences Corp, Mobileye NV, Second Sight Medical Products Inc., Consol Energy and TASER International Released By InvestorsObserver
PR Newswire - Fri Dec 18, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AVXL, MBLY, EYES, CNX and TASR.
EYES: 6.84 (-0.32), CNX: 7.38 (+0.48), AVXL: 7.49 (+0.03), TASR: 16.89 (-0.09), MBLY: 40.62 (+0.46)
Epilepsy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfmq9k/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Epilepsy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Epilepsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aequus Pharmaceuticals Inc. - Aestus Therapeutics, Inc. - Alexza Pharmaceuticals, Inc. - Allergan Plc - Anavex Life Sciences Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Biscayne Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - Epirus Biopharmaceuticals, Inc. - Glialogix, Inc. - GW Pharmaceuticals Plc - H. Lundbeck A/S - Hyundai Pharmaceutical Co., Ltd. - INSYS Therapeutics, Inc. - Iproteos S.L. - Others (30) For more information visit http://www.researchandmarkets.com/research/rfmq9k/epilepsy
AGN: 306.58 (-2.93), INSY: 28.29 (-0.37), CPRX: 2.55 (-0.18), AVXL: 7.49 (+0.03), ACOR: 40.72 (+0.31), CNCE: 20.49 (+0.57), ALXA: 0.90 (unch)
3 Biotech Stocks I'm Not Buying
Todd Campbell, The Motley Fool - Motley Fool - Tue Dec 15, 11:40AM CST
Source: Flickr user stockmonkeys.com Biotech is notorious for its jaw-dropping pops and drops and for good reason: 90% of drugs fail in human clinical trials. Because most drugs fail in trials and trial failures can cause significant declines in a...
ZIOP: 8.07 (-0.19), GWPH: 66.79 (-1.90), AVXL: 7.49 (+0.03)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Mon Dec 14, 9:27AM CST
NEW YORK, NY / ACCESSWIRE / December 14, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
AVXL: 7.49 (+0.03), NRX: 1.57 (-0.09), AKBA: 12.35 (+0.66), BSI: 3.68 (-0.11)
Biotech stocks with Ground-Breaking Potential
ACCESSWIRE - Mon Dec 14, 9:23AM CST
LAS VEGAS, NV / ACCESSWIRE / December 14, 2015 / The Regenerative Medicine Market is expected to increase from US$2.6 billion in 2012 to US$6.5 billion by 2019, according to Transparency Market Research. The Regenerative Medicine Market is being driven by several technological advancements in stem cell therapy and tissue engineering.
PIRS: 2.39 (+0.06), AVXL: 7.49 (+0.03), HART: 2.12 (+0.12), GIGA: 1.49 (-0.04)
Innovative Therapies, Diagnostics, and Events Propel These Hot Promising Small Caps
ACCESSWIRE - Wed Dec 09, 6:50AM CST
SALT LAKE CITY, UT / ACCESSWIRE / December 9, 2015 / An array of small biotech companies are making waves in the industry by presenting new, alternative medicines and therapies that perform better than their predecessors, while often available at a lower cost.
AVXL: 7.49 (+0.03)
Do Eli Lilly and Biogen Have Alzheimer's All Wrong? Anavex Life Sciences Thinks So.
Cory Renauer, The Motley Fool - Motley Fool - Mon Dec 07, 9:14AM CST
Image source: Wikimedia Commons. Recently, Anavex Life Sciences stock popped nearly 30% after presenting some encouraging results from one of its Alzheimer's candidates. It's not uncommon for promising Alzheimer's results to move a stock. What...
BIIB: 293.37 (-3.80), AVXL: 7.49 (+0.03), LLY: 84.77 (-1.45)
Covered Call Alerts For Anavex Life Sciences Corp, Skyworks Solutions, Amazon.com, and Inovio Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Dec 07, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AVXL, SWKS, AMZN, and INO.
INO: 6.87 (+0.25), AMZN: 664.14 (-6.51), SWKS: 76.38 (-1.42), AVXL: 7.49 (+0.03)
Anavex to Present at Third Annual MHPAEA Business Roundtable in Washington, D.C.
GlobeNewswire - Mon Dec 07, 7:00AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, has been invited to speak at the third annual roundtable on the implementation of the Mental Health Parity Addiction and Equity Act (MHPAEA) of 2008. The event will take place on Tuesday, December 8, 2015 at the U.S. Capitol Visitor Center in Washington, D.C.
AVXL: 7.49 (+0.03)
INVESTOR ALERT: December's Trending Biotech Stocks
ACCESSWIRE - Thu Dec 03, 12:00PM CST
CORAL GABLES, FL / ACCESSWIRE / December 3, 2015 / Biotechnology stocks have had their fair share of bumps and bruises after heavy concern surrounding pricing was brought up by several presidential candidates during the first round of debates. However, since then many stocks in this sector have taken a sharp turn in favor of the bulls. In fact, several have seen news releases on new management and even merger deals spark increased attention not only on the companies but also on the industry as a whole. Companies like VBI Vaccines Inc (VBIV), KaloBios Pharmaceuticals, Inc. (KBIO), Anavex Life Sciences Corp. (AVXL).
KBIO: 11.03 (-12.56), OPK: 9.98 (-0.06), AVXL: 7.49 (+0.03), VBIV: 2.75 (+0.19)
Anavex Life Sciences hires Ulrich Elben, PhD as VP of Preclinical Operations
M2 - Thu Dec 03, 5:30AM CST
Biopharmaceutical company Anavex Life Sciences (Other OTC:AVXL) revealed on Wednesday the election of Ulrich Elben, PhD as vice president of its Preclinical Operations, with responsibility for the pipeline development and optimisation.
VRTX: 116.51 (-1.43), AVXL: 7.49 (+0.03)
Anavex Expands Management Team
GlobeNewswire - Wed Dec 02, 8:15AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Ulrich Elben, PhD as Vice President of Preclinical Operations. In this new role, Dr. Elben will oversee the pipeline development and optimization.
AVXL: 7.49 (+0.03)
Is Anavex LIfe Sciences Corp. a Stock Worth Buying?
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 02, 7:20AM CST
Source: Flickr user stockmonkeys.com. Anavex Life Sciences Corp. 's media department has been busy lately touting the potential benefits of Alzheimer's disease drugs in its pipeline, but the company's research is in the uber-early stages. So does...
BIIB: 293.37 (-3.80), AVXL: 7.49 (+0.03)
Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics
at The Street - Wed Dec 02, 5:11AM CST
TheStreet's biotech columnist Adam Feuerstein answers readers' questions about health care.
NWBO: 4.39 (+0.18), BMRN: 104.44 (+3.80), AVXL: 7.49 (+0.03), THLD: 0.51 (-0.03)
Under Review: New NASDAQ/NYSE Stock Alert
ACCESSWIRE - Tue Dec 01, 8:45AM CST
NEW YORK, NY / ACCESSWIRE / December 1, 2015 / UltimateStockAlerts.com is a NASDAQ & NYSE investor alert service focused on day and swing trades. Receive free trade alerts via text message (SMS) or email. From your cell phone text message ULTIMATE to number 555888.
FREE: 0.02 (unch), CSC: 31.51 (+0.13), AVXL: 7.49 (+0.03)
Anavex Life Sciences (AVXL) Stock Climbs on Latest Alzheimer's Drug Results
at The Street - Mon Nov 30, 10:43AM CST
Anavex Life Sciences (AVXL) stock is soaring on heavy trading volume on Monday, after the bio-pharmaceutical company announced further data regarding its Alzheimer's drug treatment.
AVXL: 7.49 (+0.03)
Independent Research Describes ANAVEX 3-71 as Potent Cognitive Enhancer in Alzheimer's Disease Models
GlobeNewswire - Mon Nov 30, 7:00AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer, announced today the publication of further data for ANAVEX 3-71 (formerly AF710B) in the peer-reviewed scientific journal Neurodegenerative Diseases. The ANAVEX 3-71 data provides evidence for a positive, more upstream effect on reducing synaptic loss, amyloid and tau pathologies, and neuroinflammation, which is potentially beneficial for the treatment of Alzheimer's and other neurological diseases. ANAVEX 3-71 is part of the Company's pipeline including ANAVEX 2-73 targeting sigma-1 and muscarinic receptors.
AVXL: 7.49 (+0.03)
Global Biopharmaceuticals Industry
PR Newswire - Thu Nov 26, 4:19PM CST
This report analyzes the worldwide markets for Biopharmaceuticals in US$ Million by the following Segments: Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 514 companies including many key and niche players such as -
AVXL: 7.49 (+0.03), ABBV: 55.74 (-0.64)
Anavex Announces Executive Overseeing Regulatory Affairs
GlobeNewswire - Wed Nov 25, 7:08AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces that Kristina M. Capiak, CCRP has been promoted the Company's Vice President of Regulatory Affairs. She is overseeing U.S. and international regulatory matters for Anavex, including filings and interactions with the FDA and other regulatory authorities.
AVXL: 7.49 (+0.03)
Covered Call Alerts For Mobileye NV, Anavex Life Sciences Corp, SolarEdge Technologies, Microsoft and Consol Energy Released By InvestorsObserver
PR Newswire - Mon Nov 23, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for MBLY, AVXL, SEDG, MSFT and CNX.
SEDG: 26.95 (+0.87), CNX: 7.38 (+0.48), AVXL: 7.49 (+0.03), MSFT: 54.13 (-1.57), MBLY: 40.62 (+0.46)
Covered Call Alerts For Anavex Life Sciences Corp, Mobileye NV, Second Sight Medical Products Inc., Consol Energy and TASER International Released By InvestorsObserver
PR Newswire - Fri Dec 18, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AVXL, MBLY, EYES, CNX and TASR.
EYES: 6.84 (-0.32), CNX: 7.38 (+0.48), AVXL: 7.49 (+0.03), TASR: 16.89 (-0.09), MBLY: 40.62 (+0.46)
Epilepsy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfmq9k/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Epilepsy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Epilepsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aequus Pharmaceuticals Inc. - Aestus Therapeutics, Inc. - Alexza Pharmaceuticals, Inc. - Allergan Plc - Anavex Life Sciences Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Biscayne Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - Epirus Biopharmaceuticals, Inc. - Glialogix, Inc. - GW Pharmaceuticals Plc - H. Lundbeck A/S - Hyundai Pharmaceutical Co., Ltd. - INSYS Therapeutics, Inc. - Iproteos S.L. - Others (30) For more information visit http://www.researchandmarkets.com/research/rfmq9k/epilepsy
AGN: 306.58 (-2.93), INSY: 28.29 (-0.37), CPRX: 2.55 (-0.18), AVXL: 7.49 (+0.03), ACOR: 40.72 (+0.31), CNCE: 20.49 (+0.57), ALXA: 0.90 (unch)
3 Biotech Stocks I'm Not Buying
Todd Campbell, The Motley Fool - Motley Fool - Tue Dec 15, 11:40AM CST
Source: Flickr user stockmonkeys.com Biotech is notorious for its jaw-dropping pops and drops and for good reason: 90% of drugs fail in human clinical trials. Because most drugs fail in trials and trial failures can cause significant declines in a...
ZIOP: 8.07 (-0.19), GWPH: 66.79 (-1.90), AVXL: 7.49 (+0.03)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Mon Dec 14, 9:27AM CST
NEW YORK, NY / ACCESSWIRE / December 14, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
AVXL: 7.49 (+0.03), NRX: 1.57 (-0.09), AKBA: 12.35 (+0.66), BSI: 3.68 (-0.11)
Biotech stocks with Ground-Breaking Potential
ACCESSWIRE - Mon Dec 14, 9:23AM CST
LAS VEGAS, NV / ACCESSWIRE / December 14, 2015 / The Regenerative Medicine Market is expected to increase from US$2.6 billion in 2012 to US$6.5 billion by 2019, according to Transparency Market Research. The Regenerative Medicine Market is being driven by several technological advancements in stem cell therapy and tissue engineering.
PIRS: 2.39 (+0.06), AVXL: 7.49 (+0.03), HART: 2.12 (+0.12), GIGA: 1.49 (-0.04)
Innovative Therapies, Diagnostics, and Events Propel These Hot Promising Small Caps
ACCESSWIRE - Wed Dec 09, 6:50AM CST
SALT LAKE CITY, UT / ACCESSWIRE / December 9, 2015 / An array of small biotech companies are making waves in the industry by presenting new, alternative medicines and therapies that perform better than their predecessors, while often available at a lower cost.
AVXL: 7.49 (+0.03)
Do Eli Lilly and Biogen Have Alzheimer's All Wrong? Anavex Life Sciences Thinks So.
Cory Renauer, The Motley Fool - Motley Fool - Mon Dec 07, 9:14AM CST
Image source: Wikimedia Commons. Recently, Anavex Life Sciences stock popped nearly 30% after presenting some encouraging results from one of its Alzheimer's candidates. It's not uncommon for promising Alzheimer's results to move a stock. What...
BIIB: 293.37 (-3.80), AVXL: 7.49 (+0.03), LLY: 84.77 (-1.45)
Covered Call Alerts For Anavex Life Sciences Corp, Skyworks Solutions, Amazon.com, and Inovio Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Dec 07, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AVXL, SWKS, AMZN, and INO.
INO: 6.87 (+0.25), AMZN: 664.14 (-6.51), SWKS: 76.38 (-1.42), AVXL: 7.49 (+0.03)
Anavex to Present at Third Annual MHPAEA Business Roundtable in Washington, D.C.
GlobeNewswire - Mon Dec 07, 7:00AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, has been invited to speak at the third annual roundtable on the implementation of the Mental Health Parity Addiction and Equity Act (MHPAEA) of 2008. The event will take place on Tuesday, December 8, 2015 at the U.S. Capitol Visitor Center in Washington, D.C. AVXL: 7.49 (+0.03)
INVESTOR ALERT: December's Trending Biotech Stocks
ACCESSWIRE - Thu Dec 03, 12:00PM CST
CORAL GABLES, FL / ACCESSWIRE / December 3, 2015 / Biotechnology stocks have had their fair share of bumps and bruises after heavy concern surrounding pricing was brought up by several presidential candidates during the first round of debates. However, since then many stocks in this sector have taken a sharp turn in favor of the bulls. In fact, several have seen news releases on new management and even merger deals spark increased attention not only on the companies but also on the industry as a whole. Companies like VBI Vaccines Inc (VBIV), KaloBios Pharmaceuticals, Inc. (KBIO), Anavex Life Sciences Corp. (AVXL).
KBIO: 11.03 (-12.56), OPK: 9.98 (-0.06), AVXL: 7.49 (+0.03), VBIV: 2.75 (+0.19)
Anavex Life Sciences hires Ulrich Elben, PhD as VP of Preclinical Operations
M2 - Thu Dec 03, 5:30AM CST
Biopharmaceutical company Anavex Life Sciences (Other OTC:AVXL) revealed on Wednesday the election of Ulrich Elben, PhD as vice president of its Preclinical Operations, with responsibility for the pipeline development and optimisation.
VRTX: 116.51 (-1.43), AVXL: 7.49 (+0.03)
Anavex Expands Management Team
GlobeNewswire - Wed Dec 02, 8:15AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Ulrich Elben, PhD as Vice President of Preclinical Operations. In this new role, Dr. Elben will oversee the pipeline development and optimization. AVXL: 7.49 (+0.03)
Is Anavex LIfe Sciences Corp. a Stock Worth Buying?
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 02, 7:20AM CST
Source: Flickr user stockmonkeys.com. Anavex Life Sciences Corp. 's media department has been busy lately touting the potential benefits of Alzheimer's disease drugs in its pipeline, but the company's research is in the uber-early stages. So does...
BIIB: 293.37 (-3.80), AVXL: 7.49 (+0.03)
Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics
at The Street - Wed Dec 02, 5:11AM CST
TheStreet's biotech columnist Adam Feuerstein answers readers' questions about health care.
NWBO: 4.39 (+0.18), BMRN: 104.44 (+3.80), AVXL: 7.49 (+0.03), THLD: 0.51 (-0.03)
Under Review: New NASDAQ/NYSE Stock Alert
ACCESSWIRE - Tue Dec 01, 8:45AM CST
NEW YORK, NY / ACCESSWIRE / December 1, 2015 / UltimateStockAlerts.com is a NASDAQ & NYSE investor alert service focused on day and swing trades. Receive free trade alerts via text message (SMS) or email. From your cell phone text message ULTIMATE to number 555888.
FREE: 0.02 (unch), CSC: 31.51 (+0.13), AVXL: 7.49 (+0.03)
Anavex Life Sciences (AVXL) Stock Climbs on Latest Alzheimer's Drug Results
at The Street - Mon Nov 30, 10:43AM CST
Anavex Life Sciences (AVXL) stock is soaring on heavy trading volume on Monday, after the bio-pharmaceutical company announced further data regarding its Alzheimer's drug treatment.
AVXL: 7.49 (+0.03)
Independent Research Describes ANAVEX 3-71 as Potent Cognitive Enhancer in Alzheimer's Disease Models
GlobeNewswire - Mon Nov 30, 7:00AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer, announced today the publication of further data for ANAVEX 3-71 (formerly AF710B) in the peer-reviewed scientific journal Neurodegenerative Diseases. The ANAVEX 3-71 data provides evidence for a positive, more upstream effect on reducing synaptic loss, amyloid and tau pathologies, and neuroinflammation, which is potentially beneficial for the treatment of Alzheimer's and other neurological diseases. ANAVEX 3-71 is part of the Company's pipeline including ANAVEX 2-73 targeting sigma-1 and muscarinic receptors. AVXL: 7.49 (+0.03)
Global Biopharmaceuticals Industry
PR Newswire - Thu Nov 26, 4:19PM CST
This report analyzes the worldwide markets for Biopharmaceuticals in US$ Million by the following Segments: Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 514 companies including many key and niche players such as -
AVXL: 7.49 (+0.03), ABBV: 55.74 (-0.64)
Anavex Announces Executive Overseeing Regulatory Affairs
GlobeNewswire - Wed Nov 25, 7:08AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces that Kristina M. Capiak, CCRP has been promoted the Company's Vice President of Regulatory Affairs. She is overseeing U.S. and international regulatory matters for Anavex, including filings and interactions with the FDA and other regulatory authorities. AVXL: 7.49 (+0.03)
Covered Call Alerts For Mobileye NV, Anavex Life Sciences Corp, SolarEdge Technologies, Microsoft and Consol Energy Released By InvestorsObserver
PR Newswire - Mon Nov 23, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for MBLY, AVXL, SEDG, MSFT and CNX.
SEDG: 26.95 (+0.87), CNX: 7.38 (+0.48), AVXL: 7.49 (+0.03), MSFT: 54.13 (-1.57), MBLY: 40.62 (+0.46)
